JP2011529173A - 体液検査における細胞性成分の崩壊 - Google Patents
体液検査における細胞性成分の崩壊 Download PDFInfo
- Publication number
- JP2011529173A JP2011529173A JP2011519087A JP2011519087A JP2011529173A JP 2011529173 A JP2011529173 A JP 2011529173A JP 2011519087 A JP2011519087 A JP 2011519087A JP 2011519087 A JP2011519087 A JP 2011519087A JP 2011529173 A JP2011529173 A JP 2011529173A
- Authority
- JP
- Japan
- Prior art keywords
- fluid
- biological
- processed
- whole blood
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001413 cellular effect Effects 0.000 title claims abstract description 40
- 210000001124 body fluid Anatomy 0.000 title claims description 5
- 239000010839 body fluid Substances 0.000 title claims description 3
- 238000012360 testing method Methods 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 65
- 238000012545 processing Methods 0.000 claims abstract description 54
- 239000013060 biological fluid Substances 0.000 claims abstract description 49
- 239000012472 biological sample Substances 0.000 claims abstract description 10
- 239000012530 fluid Substances 0.000 claims description 96
- 210000004369 blood Anatomy 0.000 claims description 50
- 239000008280 blood Substances 0.000 claims description 50
- 239000000523 sample Substances 0.000 claims description 48
- 238000010438 heat treatment Methods 0.000 claims description 30
- 238000004140 cleaning Methods 0.000 claims description 27
- 238000007710 freezing Methods 0.000 claims description 25
- 230000008014 freezing Effects 0.000 claims description 25
- 239000012491 analyte Substances 0.000 claims description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims description 20
- 210000003743 erythrocyte Anatomy 0.000 claims description 19
- 238000004062 sedimentation Methods 0.000 claims description 13
- 238000001816 cooling Methods 0.000 claims description 12
- 238000001556 precipitation Methods 0.000 claims description 12
- 238000010257 thawing Methods 0.000 claims description 11
- 230000002776 aggregation Effects 0.000 claims description 10
- 238000004458 analytical method Methods 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 238000005119 centrifugation Methods 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 238000004925 denaturation Methods 0.000 claims description 8
- 230000036425 denaturation Effects 0.000 claims description 8
- 238000001879 gelation Methods 0.000 claims description 8
- 210000000265 leukocyte Anatomy 0.000 claims description 8
- 238000004220 aggregation Methods 0.000 claims description 7
- 210000001772 blood platelet Anatomy 0.000 claims description 7
- 239000003018 immunosuppressive agent Substances 0.000 claims description 7
- 238000005259 measurement Methods 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical group C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 claims description 6
- 230000009089 cytolysis Effects 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 238000005534 hematocrit Methods 0.000 claims description 4
- 150000002632 lipids Chemical class 0.000 claims description 4
- 238000002844 melting Methods 0.000 claims description 4
- 230000008018 melting Effects 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 4
- 238000005054 agglomeration Methods 0.000 claims description 3
- 239000012620 biological material Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 2
- 108010036949 Cyclosporine Proteins 0.000 claims description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 2
- 229960001265 ciclosporin Drugs 0.000 claims description 2
- 229930182912 cyclosporin Natural products 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 2
- 229960002930 sirolimus Drugs 0.000 claims description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims description 2
- 229960001967 tacrolimus Drugs 0.000 claims description 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 2
- 239000012930 cell culture fluid Substances 0.000 claims 1
- 238000001514 detection method Methods 0.000 abstract description 3
- 239000000306 component Substances 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 19
- 239000007788 liquid Substances 0.000 description 13
- 206010018910 Haemolysis Diseases 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 230000008588 hemolysis Effects 0.000 description 10
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 229910001220 stainless steel Inorganic materials 0.000 description 6
- 239000010935 stainless steel Substances 0.000 description 6
- 239000012808 vapor phase Substances 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 4
- 239000003570 air Substances 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- 239000012520 frozen sample Substances 0.000 description 4
- 229940050526 hydroxyethylstarch Drugs 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012062 aqueous buffer Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- -1 denature Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000012503 blood component Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000002577 cryoprotective agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003617 erythrocyte membrane Anatomy 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 description 2
- 238000000622 liquid--liquid extraction Methods 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical class O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000112 cooling gas Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910001431 copper ion Inorganic materials 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000819 hypertonic solution Substances 0.000 description 1
- 229940021223 hypertonic solution Drugs 0.000 description 1
- 239000000815 hypotonic solution Substances 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 238000010249 in-situ analysis Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 238000000348 solid-phase epitaxy Methods 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Sampling And Sample Adjustment (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8363908P | 2008-07-25 | 2008-07-25 | |
| EP08013447.1 | 2008-07-25 | ||
| US61/083,639 | 2008-07-25 | ||
| EP08013447A EP2149793A1 (en) | 2008-07-25 | 2008-07-25 | Disintegration of cellular components in body fluids |
| PCT/EP2009/005388 WO2010009895A1 (en) | 2008-07-25 | 2009-07-23 | Disintegration of cellular components in body fluids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013096139A Division JP2013174610A (ja) | 2008-07-25 | 2013-05-01 | 体液検査における細胞性成分の崩壊 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011529173A true JP2011529173A (ja) | 2011-12-01 |
| JP2011529173A5 JP2011529173A5 (enExample) | 2012-09-06 |
Family
ID=39739776
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011519087A Pending JP2011529173A (ja) | 2008-07-25 | 2009-07-23 | 体液検査における細胞性成分の崩壊 |
| JP2013096139A Pending JP2013174610A (ja) | 2008-07-25 | 2013-05-01 | 体液検査における細胞性成分の崩壊 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013096139A Pending JP2013174610A (ja) | 2008-07-25 | 2013-05-01 | 体液検査における細胞性成分の崩壊 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9012137B2 (enExample) |
| EP (2) | EP2149793A1 (enExample) |
| JP (2) | JP2011529173A (enExample) |
| CN (3) | CN103823072B (enExample) |
| CA (1) | CA2731060A1 (enExample) |
| WO (1) | WO2010009895A1 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013174610A (ja) * | 2008-07-25 | 2013-09-05 | Thermo Finnigan Llc | 体液検査における細胞性成分の崩壊 |
| KR20170129751A (ko) * | 2015-03-02 | 2017-11-27 | 코로나리콘셉츠 엘엘씨 | Peg 대사산물 및 peg 분해 생성물 검정을 위한 화합물 및 방법 |
| JP2019537000A (ja) * | 2016-10-11 | 2019-12-19 | ハエモキネシス・ピーティーワイ．・リミテッド | レーザを使用した試料、標本、及び試薬のインキュベーションを増進するための方法 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9702864B2 (en) * | 2014-12-19 | 2017-07-11 | Thermo Finnigan Llc | Means for generating cell-disintegrated blood |
| CN106706381B (zh) * | 2016-11-09 | 2019-04-12 | 桂林理工大学 | 植物亚细胞中总可溶性酚的分离提取方法 |
| US20210180001A1 (en) * | 2018-04-23 | 2021-06-17 | Univercells Technologies S.A. | Bioreactor with freeze-thaw capabilities to enhance product recovery and related methods |
| US11578011B2 (en) | 2018-08-15 | 2023-02-14 | The Regents Of The University Of Michigan | Freeze concentration for urine-based fertilizer production |
| US11897822B2 (en) | 2019-11-07 | 2024-02-13 | The Regents Of The University Of Michigan | Reciprocating freeze concentration for urine-based fertilizer production |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04300896A (ja) * | 1991-03-29 | 1992-10-23 | Hiroshi Sueoka | ヒト由来の早期妊娠因子及びその分離・精製法 |
| JP2001296292A (ja) * | 2001-03-26 | 2001-10-26 | Horiba Ltd | 免疫測定方法 |
| JP2004117127A (ja) * | 2002-09-25 | 2004-04-15 | Limuloid Science Kk | 血液エンドトキシン測定方法 |
| JP2007510149A (ja) * | 2003-10-31 | 2007-04-19 | プラズマキュート エイエス | アッセイ |
| WO2008003451A1 (en) * | 2006-07-03 | 2008-01-10 | Sebo Gmbh | A method and device for processing a biological fluid for analyte determination |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5151348A (en) * | 1988-12-23 | 1992-09-29 | E. I. Du Pont De Nemours And Company | Enzyme-linked immunoassay for measurement of cyclosporin a levels in whole blood samples |
| US6403376B1 (en) * | 1998-11-16 | 2002-06-11 | General Hospital Corporation | Ultra rapid freezing for cell cryopreservation |
| JP3614016B2 (ja) * | 1999-02-01 | 2005-01-26 | ニプロ株式会社 | 凍結細胞から有用細胞を回収する方法およびそのための器具 |
| US6623945B1 (en) | 1999-09-16 | 2003-09-23 | Motorola, Inc. | System and method for microwave cell lysing of small samples |
| CN1381239A (zh) * | 2001-04-18 | 2002-11-27 | 松元司 | 由培养的白细胞提取成分的方法 |
| US20060166367A1 (en) * | 2005-01-27 | 2006-07-27 | Neogen Corporation | Protein assay method and test device |
| CN101105457B (zh) * | 2007-07-30 | 2011-01-19 | 南昌大学 | 一种改良bca-紫外结合法测定氨苄青霉素人工抗原偶联率的方法 |
| EP2149793A1 (en) * | 2008-07-25 | 2010-02-03 | SeBo GmbH | Disintegration of cellular components in body fluids |
-
2008
- 2008-07-25 EP EP08013447A patent/EP2149793A1/en not_active Ceased
-
2009
- 2009-07-23 EP EP09800016.9A patent/EP2310863B1/en not_active Not-in-force
- 2009-07-23 CN CN201410050570.1A patent/CN103823072B/zh not_active Expired - Fee Related
- 2009-07-23 CA CA2731060A patent/CA2731060A1/en not_active Abandoned
- 2009-07-23 JP JP2011519087A patent/JP2011529173A/ja active Pending
- 2009-07-23 CN CN200980129078.0A patent/CN102105796B/zh not_active Expired - Fee Related
- 2009-07-23 WO PCT/EP2009/005388 patent/WO2010009895A1/en not_active Ceased
- 2009-07-23 US US13/003,859 patent/US9012137B2/en not_active Expired - Fee Related
- 2009-07-23 CN CN201510621231.9A patent/CN105258989A/zh active Pending
-
2013
- 2013-05-01 JP JP2013096139A patent/JP2013174610A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04300896A (ja) * | 1991-03-29 | 1992-10-23 | Hiroshi Sueoka | ヒト由来の早期妊娠因子及びその分離・精製法 |
| JP2001296292A (ja) * | 2001-03-26 | 2001-10-26 | Horiba Ltd | 免疫測定方法 |
| JP2004117127A (ja) * | 2002-09-25 | 2004-04-15 | Limuloid Science Kk | 血液エンドトキシン測定方法 |
| JP2007510149A (ja) * | 2003-10-31 | 2007-04-19 | プラズマキュート エイエス | アッセイ |
| WO2008003451A1 (en) * | 2006-07-03 | 2008-01-10 | Sebo Gmbh | A method and device for processing a biological fluid for analyte determination |
Non-Patent Citations (1)
| Title |
|---|
| JPN6013003993; Ｍ． Ｗ． ＳＣＨＥＩＷＥ: 'Ａｎ Ｅｘｐｅｒｉｍｅｎｔａｌ Ｓｔｕｄｙ ｏｎ ｔｈｅ Ｆｒｅｅｚｉｎｇ ｏｆ Ｒｅｄ Ｂｌｏｏｄ Ｃｅｌｌｓ ｗｉｔｈ ａｎｄ ｗｉｔｈｏｕｔ Ｈｙｄｒｏｘｙｅｔｈｙｌ Ｓｔａｒｃｈ' ＣＲＹＯＢＩＯＬＯＧＹ Ｖｏｌ．１９／Ｎｏ．５, 1982, ４６１-４７７ * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013174610A (ja) * | 2008-07-25 | 2013-09-05 | Thermo Finnigan Llc | 体液検査における細胞性成分の崩壊 |
| KR20170129751A (ko) * | 2015-03-02 | 2017-11-27 | 코로나리콘셉츠 엘엘씨 | Peg 대사산물 및 peg 분해 생성물 검정을 위한 화합물 및 방법 |
| JP2018507410A (ja) * | 2015-03-02 | 2018-03-15 | コロナリーコンセプツ エルエルシー | Ｐｅｇ代謝物及びｐｅｇ分解生成物のアッセイのための化合物並びに方法 |
| KR102091852B1 (ko) * | 2015-03-02 | 2020-03-23 | 코로나리콘셉츠 엘엘씨 | Peg 대사산물 및 peg 분해 생성물 검정을 위한 화합물 및 방법 |
| US10663438B2 (en) | 2015-03-02 | 2020-05-26 | Colonaryconcepts Llc | Compounds and methods for PEG metabolite and PEG breakdown product assays |
| JP2019537000A (ja) * | 2016-10-11 | 2019-12-19 | ハエモキネシス・ピーティーワイ．・リミテッド | レーザを使用した試料、標本、及び試薬のインキュベーションを増進するための方法 |
| JP2023002576A (ja) * | 2016-10-11 | 2023-01-10 | ハエモキネシス・リミテッド | レーザを使用した試料、標本、及び試薬のインキュベーションを増進するための方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103823072A (zh) | 2014-05-28 |
| EP2310863B1 (en) | 2015-01-21 |
| CA2731060A1 (en) | 2010-01-28 |
| EP2149793A1 (en) | 2010-02-03 |
| CN102105796B (zh) | 2015-10-14 |
| JP2013174610A (ja) | 2013-09-05 |
| CN102105796A (zh) | 2011-06-22 |
| US9012137B2 (en) | 2015-04-21 |
| EP2310863A1 (en) | 2011-04-20 |
| WO2010009895A1 (en) | 2010-01-28 |
| CN103823072B (zh) | 2016-05-11 |
| US20110229870A1 (en) | 2011-09-22 |
| CN105258989A (zh) | 2016-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013174610A (ja) | 体液検査における細胞性成分の崩壊 | |
| Bi et al. | The key points in the pre-analytical procedures of blood and urine samples in metabolomics studies | |
| Vuckovic | Current trends and challenges in sample preparation for global metabolomics using liquid chromatography–mass spectrometry | |
| US8231838B2 (en) | Method and device for processing a biological fluid for analyte determination | |
| Alexovič et al. | Automation of single‐cell proteomic sample preparation | |
| Wang et al. | Integration of phase separation with ultrasound-assisted salt-induced liquid–liquid microextraction for analyzing the fluoroquinones in human body fluids by liquid chromatography | |
| JP2011529173A5 (enExample) | ||
| Fridjonsdottir et al. | Brain tissue sample stabilization and extraction strategies for neuropeptidomics | |
| JP2003527566A (ja) | 診断試験用球体の調製 | |
| US20070196813A1 (en) | Extraction of substances of interest from blood for mass spectrometric analysis | |
| US20120107804A1 (en) | Disintegration of cellular components in body fluids | |
| US20210239717A1 (en) | Microsampling detection in diabetes | |
| EP1876450B1 (en) | A method for processing whole blood for analyte determination | |
| HK1147313A (en) | A method and device for processing a biological fluid for analyte determination | |
| Shao et al. | Evaporative preconcentration of fluorescent protein samples in capillary based microplates | |
| Moncrieffe et al. | Quantification of insulin‐like growth factor‐I by liquid chromatography–mass spectrometry | |
| Mota-Martorell et al. | Nonenzymatic Protein Damage in Cerebrospinal Fluid | |
| Tammen et al. | Collection and handling of blood specimens for peptidomics | |
| Jain et al. | Analytical methods in the detection of proteins and peptides in tissue fluids and homogenates | |
| WO2022248979A1 (en) | Enzyme-conjugated magnetic beads suspended in internal standard buffer | |
| Timms | Plasma Extracellular Vesicles: Does Anticoagulant Type Matter? |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120723 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120723 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20121213 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130201 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20130305 |
|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20130412 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130501 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130527 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130823 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140519 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141208 |